الإحصائيات الأساسية
| LEI | 529900UG3DGE202N5D44 |
| CIK | 1813814 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mind Medicine (MindMed) Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 4, 2025 |
Exhibit 99.1 Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administratio |
|
| September 4, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 04, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporat |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medici |
|
| July 31, 2025 |
Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Mark R. Sullivan (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement dated April 13, 2023, between the Company and Executive (the “Prior Agr |
|
| July 31, 2025 |
Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Daniel Karlin M.D. (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement dated November 9, 2022, between the Company and Executive (the “Prior |
|
| July 31, 2025 |
Exhibit 10.9 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Matthew Wiley (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”) and supersedes in its entirety the Executive Employment Agreement dated March 17, 2025 between the Company and Executive (the “Prior Agreement |
|
| July 31, 2025 |
Corporate Presentation August 2025 Corporate Presentation August 2025 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. |
|
| July 31, 2025 |
Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Robert Barrow (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement between the Company and Executive dated November 9, 2022 (the “Prior Agreem |
|
| July 31, 2025 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective May 27, 2025 (the “Effective Date”), by and between Brandi L. Roberts (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to th |
|
| July 31, 2025 |
Exhibit 99.1 MindMed Reports Q2 2025 Financial Results and Business Updates -Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)- -Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD an |
|
| July 31, 2025 |
Form of Option Agreement granted as an Inducement Award. Exhibit 10.10 MIND MEDICINE (MINDMED) INC. Inducement AWARD NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting |
|
| July 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
Exhibit 99.3 MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN RESTRICTED SHARE Unit Agreement COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants restricted share units (the “RSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subjec |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mind Medicine (MindMed) Inc. |
|
| June 20, 2025 |
Form of Stock Option Award Agreement to Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan. Exhibit 99.2 MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to th |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| June 16, 2025 |
Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan. MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its shareholders and other important stakeholders, including its employees |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) ( |
|
| May 27, 2025 |
Exhibit 99.1 MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer NEW YORK, May 27, 2025 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief F |
|
| May 8, 2025 |
Form of Restricted Share Unit Award Agreement granted as an Inducement Award. Exhibit 10.3 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT RSU AWARD AGREEMENT This RSU Award Agreement is entered into between Mind Medicine (MindMed) Inc. (the "Corporation") and the RSU Holder named below. Your Award has been granted as an inducement that is material to your employment with the Corporation pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora |
|
| May 8, 2025 |
Form of Performance Share Unit Award Agreement to Performance and Restricted Share Unit Plan. Exhibit 10.1 MIND MEDICINE (MINDMED) INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PSU Award Agreement (the “PSU Award Agreement”) is entered into between Mind Medicine (MindMed) Inc. (the “Corporation”) and the Participant named below pursuant to the Performance and Restricted Share Unit Plan of the Corporation (the "Plan") effective March 7, 2023, as |
|
| May 8, 2025 |
Exhibit 99.1 MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates -Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026- -Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week top |
|
| May 8, 2025 |
Form of Option Agreement granted as an Inducement Award. Exhibit 10.4 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT NONSTATUTORY STOCK OPTION AGREEMENT Your Option has been granted as an “inducement” award pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and not pursuant to the Mind Medicine (MindMed) Inc. Stock Option Plan (the “Plan”) or any equity incentive plan of the Corporation, as an inducement that is material |
|
| May 8, 2025 |
Form of Performance Share Unit Award Agreement granted as an Inducement Award. Exhibit 10.2 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This PSU Award Agreement (the “PSU Award Agreement”) is entered into between Mind Medicine (MindMed) Inc. (the “Corporation”) and the Participant named below. The PSUs (as defined below) have been granted to the Participant as an inducement that is material to the Participant’s employment with the Cor |
|
| May 8, 2025 |
Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective March 17, 2025 (the “Effective Date”), by and between Matthew Wiley (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to the |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medic |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| April 21, 2025 |
Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST Amendment to Loan and security agreement This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 18, 2025 (the “Restatement Effective Date”), by and among MIND MEDIC |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| April 15, 2025 |
Exhibit 99.1 MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 Orally Disintegrating Tablet (ODT) 100 µg and placebo - - Emerge builds o |
|
| April 15, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| March 6, 2025 |
Exhibit 99.1 MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates -First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama- -On track to initiate Emerge, the first Phase 3 study of MM120 ODT |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine ( |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| March 6, 2025 |
Description of Capital Stock of Mind Medicine (MindMed) Inc. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Mind Medicine (MindMed) Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securitie |
|
| March 6, 2025 |
MIND MEDICINE (MINDMED) INC. INSIDER TRADING POLICY As amended and restated, effective July 25, 2022 Doc. No. P-CG-002 Rev. No. 002 Effective: 07/25/2022 I. Introduction During the course of your employment, directorship or consultancy with Mind Medicine (MindMed) Inc. (the “Company”), you may receive important information that is not yet publicly available (“inside information”) about the Company |
|
| January 30, 2025 |
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Panorama builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 and will be conducted at sites in the US and Europe - - Topline data from the 12-week double-blind period anticipated in the second half of 2026 - NEW YORK – Mind Medicine (MindMed) Inc. |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio |
|
| January 13, 2025 |
Corporate Presentation January 2025 Exhibit 99.1 Corporate Presentation January 2025 Corporate Presentation | January 2025 This presentation (the “Presentation”) has been prepared by Mind Medicine ( MindMed ) Inc. (“ MindMed ”, the “Company”, “we”, “our” or “us) solely for informational purposes. This Presentation does not constitute an offering of , o r a solicitation of an offer to purchase, securities of MindMed and under no circ |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio |
|
| December 16, 2024 |
Exhibit 99.1 MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Study builds on p |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporati |
|
| November 14, 2024 |
MNMD / Mind Medicine (MindMed) Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 60255C885 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind M |
|
| November 7, 2024 |
Exhibit 99.1 MindMed Reports Third Quarter 2024 Financial Results and Business Updates -On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026- -On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge s |
|
| November 7, 2024 |
Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Warrant No. [●] Number of Shares: [●] (subject to adjustment) Original Issue Date: October [●], 2024 Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco |
|
| October 22, 2024 |
Up to 5,497,506 Common Shares Offered by the Selling Stockholders Filed pursuant to Rule 424(b)(3) Registration No. 333-278468 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 30, 2024) Up to 5,497,506 Common Shares Offered by the Selling Stockholders This prospectus supplement supplements the information contained in the prospectus dated April 30, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (Registration No. 333-278468 |
|
| October 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(7) (Form Type) MindMed (Mind Medicine) Inc. |
|
| October 17, 2024 |
Up to 8,000,000 Common Shares Offered by the Selling Stockholders TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-280548 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 28, 2024) Up to 8,000,000 Common Shares Offered by the Selling Stockholders This prospectus supplement relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus supplement under the caption “Selling Stockholders,” of up to 8 |
|
| October 17, 2024 |
Exhibit 4.1 Final Form NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco |
|
| October 17, 2024 |
Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO THE REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Registration Rights Agreement (this “Amendment No. 1”) is made and entered into as of October 17, 2024, by and between Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each of the several purchasers s |
|
| October 17, 2024 |
Exhibit 10.1 Execution Version October 17, 2024 Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 Re: Warrant Exchange Agreement Ladies and Gentlemen: This letter agreement (this “Agreement”) confirms the agreement of Mind Medicine (MindMed) Inc. (the “Company”), and the holders of the common shares, without par value, of the Company listed on Schedule I attached he |
|
| August 13, 2024 |
Notice of Articles, Incorporated on July 26, 2010, effective as of July 30, 2024. EX-3.2 2 mnmd-ex32.htm EX-3.2 Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor |
|
| August 13, 2024 |
Exhibit 99.1 MindMed Reports Second Quarter 2024 Financial Results and Business Updates -Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024- -Expanding pipeline with MM120 ODT clinical program in Major Dep |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medici |
|
| August 13, 2024 |
Exhibit 10.3 SEPARATION AGREEMENT CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. May 3, 2024 Amended May 28, 2024 Schond Greenway [***] [***] Re: Separation Agreement Dear Schond: This Agreement (the “Agreement”) sets forth the terms and conditions of your separat |
|
| August 12, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Warrant No. [·] Number of Shares: [·] (subject to adjustment) Original Issue Date: [·], 2024 Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, |
|
| August 12, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-280548 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 28, 2024) 9,285,511 Common Shares Pre-Funded Warrants to Purchase 1,428,775 Common Shares MindMed (Mind Medicine) Inc. We are offering 9,285,511 common shares, without par value, at a public offering price of $7.00 per share and, to certain investors, pre-funded warrants |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| August 12, 2024 |
Exhibit 1.1 Mind Medicine (MindMed) Inc. 9,285,511 Common Shares (no par value per share) Pre-Funded Warrants to Purchase 1,428,775 Common Shares Underwriting Agreement New York, New York August 9, 2024 Leerink Partners LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed on Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New Y |
|
| August 12, 2024 |
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering Exhibit 99.2 Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering NEW YORK, August 9, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value |
|
| August 12, 2024 |
Corporate Presentation August 2024 Exhibit 99.3 Corporate Presentation August 2024 Corporate Presentation | August 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine ( MindMed ) Inc. (“ MindMed ”, the “Company”, “we”, “our” or “us) solely for informational purposes. This Presentation does not constitute an offering of , o r a solicitation of an offer to purchase, securities of MindMed and unde |
|
| August 12, 2024 |
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering Exhibit 99.1 Mind Medicine (MindMed) Inc. Announces Proposed Public Offering NEW YORK, August 9, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain |
|
| August 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Mind Medicine (MindMed) Inc. |
|
| August 9, 2024 |
SUBJECT TO COMPLETION, DATED AUGUST 9, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mind Medicine (MindMed) Inc. |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor |
|
| June 28, 2024 |
Mind Medicine (MindMed) Inc. Employee Share Purchase Plan Exhibit 99.5 MIND MEDICINE (MINDMED) INC. 2024 EMPLOYEE SHARE PURCHASE PLAN 1. PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Affiliates may be given an opportunity to purchase Common Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. I |
|
| June 28, 2024 |
Exhibit 1.2 Mind Medicine (MindMed) Inc. Common Shares (no par value per share) Sales Agreement June 28, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 28, 2024 |
Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN MIND MEDICINE (MINDMED) INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section |
|
| June 28, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) Mind Medicine (MindMed) Inc. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| June 20, 2024 |
Exhibit 99.1 MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) -Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- NEW YORK, June 20, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindM |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medic |
|
| May 8, 2024 |
Exhibit 99.1 MindMed Reports First Quarter 2024 Financial Results and Business Updates -Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment- -The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment o |
|
| April 30, 2024 |
Up to 13,497,506 Common Shares Offered by the Selling Stockholders TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-278468 PROSPECTUS Up to 13,497,506 Common Shares Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 13,497,506 of our common shares, no par value per share (the “common |
|
| April 30, 2024 |
Up to 13,497,506 Common Shares Offered by the Selling Stockholders TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-278468 PROSPECTUS Up to 13,497,506 Common Shares Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 13,497,506 of our common shares, no par value per share (the “common |
|
| April 26, 2024 |
Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 April 26, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Mind Medicine (MindMed) Inc. Registration Statement on Form S-3 Filed April 2, 2024 File No. 333-278468 Request for Acceleration of |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 2, 2024 |
Exhibit 107 Form S-3 (Form Type) Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Sha |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 2, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 2, 2024 Registration No. |
|
| April 1, 2024 |
Exhibit 99.1 MindMed Announces Voluntary Delisting from Cboe Canada All Common shares will remain listed on Nasdaq NEW YORK, April 1, 2024 -(BUSINESS WIRE)- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected t |
|
| April 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) |
|
| March 21, 2024 |
MNMD / Mind Medicine (MindMed) Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 60255C885 (CUSIP Number) March 11, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| March 15, 2024 |
MNMD / Mind Medicine (MindMed) Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2024 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 7, 2024, by and between MIND MEDICINE (MINDMED) INC., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo |
|
| March 11, 2024 |
Exhibit 1.1 Mind Medicine (MindMed) Inc. 16,666,667 Common Shares (no par value per share) Underwriting Agreement New York, New York March 7, 2024 Leerink Partners LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed on Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 c/o Cantor Fitzgerald & Co. 110 East 59th S |
|
| March 11, 2024 |
EX-99.1 Exhibit 99.1 Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement NEW YORK, March 7, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the prici |
|
| March 11, 2024 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 7, 2024, by and between Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collecti |
|
| March 8, 2024 |
16,666,667 Common Shares MindMed (Mind Medicine) Inc. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264648 Registration No. 333-277726 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 16, 2022) 16,666,667 Common Shares MindMed (Mind Medicine) Inc. We are offering 16,666,667 common shares, no par value per share, at a public offering price of $6.00 per share. Our common shares are listed on the Nasdaq Global Select Market |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo |
|
| March 7, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 S-3MEF As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 7, 2024 |
EX-99.1 Exhibit 99.1 MM120 for Generalized Anxiety Disorder (GAD) Phase 2b Full Topline Data ODT PK Bridging Study Breakthrough Therapy Designation March 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective |
|
| March 7, 2024 |
EX-99.2 Exhibit 99.2 MM120 for GAD Investor Presentation March 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives |
|
| March 7, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-3 MIND MEDICINE (MINDMED) INC. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo |
|
| March 7, 2024 |
EX-99.1 Exhibit 99.1 THURSDAY MARCH 7, 2023, 6:00 AM EST MINDMED RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION AND ANNOUNCES POSITIVE 12-WEEK DURABILITY DATA FROM PHASE 2B STUDY OF MM120 FOR GENERALIZED ANXIETY DISORDER -A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 we |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc |
|
| February 28, 2024 |
Notice of Articles, Incorporated on July 26, 2010, effective as of August 18, 2023. Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Cover Sheet MIND MEDICINE (MINDMED) INC. Confirmation of Service Form Filed: Notice of Change of Address Date and Time of Filing: August 17, 2023 04:53 PM Pacific Time Effective Date: Specified Date and Time of Filing: August |
|
| February 28, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Mind Medicine (MindMed) Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securitie |
|
| February 28, 2024 |
Form of Mind Medicine (MindMed) Inc. Common Share Certificate. Exhibit 4.2 C0000000230 | M Number 00000000 THIS CERTIFIES THAT MIND MEDICINE (MINDMED) INC. A BRITISH COLUMBIA COMPANY Shares * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * IS THE REGISTERED HOLDER OF FULLY PAID AND NON-ASSESSABLE COMMON SHARES WITHOUT PAR VALUE IN THE CAPITAL OF MIND MEDICINE (MINDMED) I |
|
| February 28, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 Mind Medicine (MindMed) Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Poli |
|
| February 28, 2024 |
Exhibit 99.1 MindMed Reports 2023 Financial Results and Business Updates -Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)- -Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine ( |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor |
|
| January 8, 2024 |
Exhibit 99.1 MindMed Announces Business Update and Anticipated Milestones for 2024 - Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program - - Proof-of-Concept study evaluating repeated sub-percept |
|
| December 14, 2023 |
EX-99.2 Exhibit 99.2 MM-120 for Generalized Anxiety Disorder (GAD) Phase 2b Topline Data December 2023 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not b |
|
| December 14, 2023 |
EX-99.1 Exhibit 99.1 MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder – Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, represe |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or other jurisdiction of inc |
|
| November 2, 2023 |
Logo Third Quarter 2023 Financial Results and Business Update November 2, 2023 Exhibit 99.2 Logo Third Quarter 2023 Financial Results and Business Update November 2, 2023 Disclaimer This presentation (the “Presentation”) has been preparedby Mind Medicine(MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representat |
|
| November 2, 2023 |
Exhibit 99.1 MindMed Reports Third Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Cash and cash equivalents of $117.7 million at September 30, 202 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc |
|
| August 14, 2023 |
Company Logo MindMed Investor Presentation August 2023 Exhibit 99.1 Company Logo MindMed Investor Presentation August 2023 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes a |
|
| August 14, 2023 |
K2 HealthVentures LLC Loan and Security Agreement CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| August 14, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) New York 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) New York 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 3, 2023 |
Exhibit 99.1 MindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Entered into exclusiv |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| August 3, 2023 |
Directors' Deferred Share Unit Plan, amended as of June 8, 2023 Exhibit 10.3 DIRECTORS’ DEFERRED SHARE UNIT PLAN EFFECTIVE AS OF APRIL 16, 2021 AMENDED AS OF JUNE 8, 2023 1. DEFINITIONS a. When used herein, the following terms shall have the following meanings: i. “Associated Company” means any subsidiary or affiliate of the Company. ii. “Administrator” means the Board or, if so delegated by the Board to administer the Plan, the Compensation Committee, or any |
|
| August 3, 2023 |
Non-Employee Director Compensation Policy, amended as of June 8, 2023 Exhibit 10.2 Mind Medicine (MindMed) Inc. Non-Employee Director Compensation Policy Effective as of June 1, 2022 Amended August 11, 2022 Amended June 8, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Mind Medicine (MindMed) Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medici |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| June 20, 2023 |
MindMed Investor Presentation Investor Day 2023: MM-120 for Generalized Anxiety Disorder Exhibit 99.1 MindMed Investor Presentation Investor Day 2023: MM-120 for Generalized Anxiety Disorder Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 16, 2023 |
DEFA14AJune 16 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| June 15, 2023 |
DEFA14AJune 15 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 15, 2023 |
Exhibit 99.1 MindMed Adjourns Annual General Meeting of Shareholders Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’s Director Candidates on the WHITE Universal Proxy Card NEW YORK, June 15, 2023 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 8, 2023 | ||
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 31, 2023 | ||
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 30, 2023 |
Q6ĥ ĥ ĥ¹ Å ĥ ĥ ĥ āE- Cĥ ĥ 2ĥ´ĥ ¬ - Cĥĥ $- ĥ$Ä ĥ Ûĥ ĥĥ >1ĥ @ĥ ĥÕ ĥë Jz ĥ ĥ ĥ ĥ ĥ ĥ ĥ ĥ ĥ ĥ ĥ /Ĥñĥ È ĥ½#ĥ° ĥ ĥª9 ăĥ ?óĥĥ ĥ ĥ R ĥ ĥĥ ĥ(ĥ# ĥ9 , ĥ Âkĥ 9 wĥ $ĥå ĥ ĥÆÒĥĥ ĥ Xĥ Gĥ$éiĥ # |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 25, 2023 |
DEFA14A 1 mnmdgreenleafprmay2.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 24, 2023 | ||
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor |
|
| May 24, 2023 |
Exhibit 99.1 MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-402 – NEW YORK, May 24, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing nov |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 17, 2023 |
Exhibit 99.1 MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 – NEW YORK, May 17, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel p |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor |
|
| May 15, 2023 |
Drug Name Active Ingredient Approval Date FDA-approved use on approval date* Prepopik sodium picosulfate, magnesium oxide and citric acid 7/16/2012 To help cleanse the colon in adults preparing for colonoscopy. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 5, 2023 |
LETTER TO STOCKHOLDERS, DATED MAY 5, 2023 FCM FCM MM HOLDINGS, LLC May 5, 2023 Dear Fellow MindMed Shareholders, FCM MM Holdings, LLC and its affiliates (collectively, “FCM”) beneficially own 1,368,538 shares of Mind Medicine (MindMed) Inc. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Med |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 4, 2023 |
Exhibit 99.1 MindMed Reports First Quarter 2023 Financial Results and Business Highlights – Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 – – MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting – – Strengthened leadership team with appointment of Mark R. Sullivan as Chief Legal Officer – – Cash and cash equivalents of $129.4 million |
|
| May 4, 2023 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective April 13, 2023 (the “Effective Date”), by and between Mark R. Sullivan (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to the Company |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| May 2, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 2, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confid |
|
| May 1, 2023 |
PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 1, 2023 |
DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2023 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com April 28, 2023 Office of Mergers and Acquisitions Division of Corporation Finance U. |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide |
|
| April 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2023 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorporat |
|
| April 18, 2023 |
PREC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2023 |
EX-99.1 Exhibit 99.1 MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and Highly Qualified, New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and Enhance Shareholder Value Discloses FCM MM HOLDINGS’ Intent to Take Control of the Boar |
|
| April 18, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2023 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of In |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| April 14, 2023 |
99.1 MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) – Primary endpoint achieved statistically significant improvement in MDD symptoms – – Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) – – Data presented on April 14, |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| March 14, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mind Medicine (MindMed) Inc. |
|
| March 14, 2023 |
Powers of Attorney (included on the signature page). S-8 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo |
|
| March 9, 2023 |
Exhibit 10.16 MIND MEDICINE (MINDMED) INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN 1. PREAMBLE AND DEFINITIONS 1.1 Title and Conflict. The Plan described in this document shall be called the “Performance and Restricted Share Unit Plan”. In the event of any conflict or inconsistency between the Plan described in this document and the Award Agreement (as defined below), the terms and conditions o |
|
| March 9, 2023 |
Exhibit 4.8 THIS SUPPLEMENTAL INDENTURE is dated as of the 26th day of August, 2022 BETWEEN: MIND MEDICINE (MINDMED) INC., a company existing under the laws of British Columbia (hereinafter called the “Company”) -and - COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company existing under the laws of Canada and authorized to carry on business in all provinces as Canada (hereinafter called the “Warr |
|
| March 9, 2023 |
Description of Capital Stock of Mind Medicine (MindMed) Inc. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Mind Medicine (MindMed) Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securitie |
|
| March 9, 2023 |
Notice of Articles, Incorporated on July 26, 2010, as altered on June 30, 2022. Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Cover Sheet MIND MEDICINE (MINDMED) INC. Confirmation of Service Form Filed: Notice of Alteration Date and Time of Filing: June 28, 2022 02:12 PM Pacific Time Alteration Effective Date: Specified Date and Time of Alteration: |
|
| March 9, 2023 |
99.1 MindMed Reports Full Year 2022 Financial Results and Business Highlights – Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to initiate first clinical trial of MM-402 in 2023 – – Cash and cash equivalents of $142.1 million at December 31, 2022 – – Company to host conference call today at 4:30 PM ET – NEW YORK, March 9, 2 |
|
| March 9, 2023 |
Mind Medicine (MindMed) Inc. Stock Option Plan (as amended and restated on March 7, 2023). Exhibit 10.15 MIND MEDICINE (MINDMED) INC. STOCK OPTION PLAN 1. Interpretation In this Plan, the following terms shall have the following meanings: “Administrators” means the Board or, if so designated by the Board to administer the Plan, the Compensation Committee of the Board or any other designated members of the Board; “Associate” has the meaning assigned by the Securities Act (Ontario); “Boar |
|
| March 9, 2023 |
Exhibit 4.10 THIS SUPPLEMENTAL INDENTURE is dated as of the 26th day of August, 2022 BETWEEN: MIND MEDICINE (MINDMED) INC., a company existing under the laws of British Columbia (hereinafter called the “Company”) -and - COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company existing under the laws of Canada and authorized to carry on business in all provinces as Canada (hereinafter called the “War |
|
| March 9, 2023 |
Form of Mind Medicine (MindMed) Inc. Common Share Certificate. Exhibit 4.2 C0000000230 | M Number 00000000 THIS CERTIFIES THAT MIND MEDICINE (MINDMED) INC. A BRITISH COLUMBIA COMPANY Shares * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * IS THE REGISTERED HOLDER OF FULLY PAID AND NON-ASSESSABLE COMMON SHARES WITHOUT PAR VALUE IN THE CAPITAL OF MIND MEDICINE (MINDMED) I |
|
| March 9, 2023 |
Mind Medicine (MindMed), Inc. Option Plan. EX-10 8 mnmd-ex102.htm EX-10.2 Exhibit 10.2 MIND MEDICINE (MINDMED) INC. STOCK OPTION PLAN 1. Interpretation In this Plan, the following terms shall have the following meanings: “Administrators” means the Board or, if so designated by the Board to administer the Plan, the Compensation Committee of the Board or any other designated members of the Board; “Associate” has the meaning assigned by the S |
|
| March 9, 2023 |
Exhibit 4.9 THIS SUPPLEMENTAL INDENTURE is dated as of the 26th day of August, 2022 BETWEEN: MIND MEDICINE (MINDMED) INC., a company existing under the laws of British Columbia (hereinafter called the “Company”) -and - COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company existing under the laws of Canada and authorized to carry on business in all provinces as Canada (hereinafter called the “Warr |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine ( |
|
| March 9, 2023 |
Form of Option Agreement to Mind Medicine (MindMed) Inc. Stock Option Plan. Exhibit 10.17 MIND MEDICINE (MINDMED) INC. STOCK OPTION PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Mind Medicine (MindMed) Inc. Stock Option Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement, which includes this Notice of Stock Option Grant (the “Notice of Grant”). NOTICE GRANT Participant: [[FIRSTNAME]] [[LASTNAME]] Add |
|
| February 14, 2023 |
CA60255C8850 / MIND MEDICINE MINDMED INC / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 60255C885 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 60255C885 (CUSIP Number) Dece |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora |
|
| January 9, 2023 |
EX-99.1 Exhibit 99.1 MindMed Provides Corporate Update and 2023 Outlook - Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial of MM-402 in 2023 - Cash runway to fund current operating plan into first half of 2025 - Company to host a virtual analyst and investor day in the first half of 2023 NEW YOR |
|
| November 10, 2022 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective November 9, 2022 (the “Effective Date”), by and between Daniel Karlin, M.D. (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Employment Agreement dated June 25, 2019, between HealthMode, Inc. (as assigned to the Company) and Execut |
|
| November 10, 2022 |
Exhibit10.4 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective November 9, 2022 (the “Effective Date”), by and between Schond Greenway (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Offer of Employment Agreement dated May 9, 2022, between the Company and Executive (the “Prior Agreement”). The |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc |
|
| November 10, 2022 |
99.1 MindMed Reports Third Quarter 2022 Financial Results and Business Highlights – Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder with first patients dosed in Q3 2022 and expect key clinical readout in late 2023 – – Advanced IND-enabling studies for MM-402 and initiated Phase 1 investigator-initiated trial in Q3 2022 – – Cash and cash equivalents of $154.5 million |
|
| November 10, 2022 |
Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into effective November 9, 2022 (the “Effective Date”), by and between Miri Halperin Wernli, Ph.D. (the “Executive”) and MindMed Discover LLC (the “Company”), and amends and restates in its entirety the Executive Employment Agreement between the Company and E |
|
| November 10, 2022 |
Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective November 9, 2022 (the “Effective Date”), by and between Carrie Liao (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Offer Letter dated October 20, 2021, between the Company and Executive (the “Prior Agreement”). The Company desire |
|
| November 10, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into effective November 9, 2022 (the “Effective Date”), by and between Robert Barrow (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Offer Letter dated January 13, 2021, between the Company and Executive, as amended by that certain Appointment L |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind M |
|
| October 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Mind Medicine (MINDMED) Inc. (Name of Issuer) COMMON SHARES, NO PAR VALUE (Title of Class of Securities) 60255C885 (CUSIP Number) Joseph D. Samberg 1091 Boston Post Road Rye, New York 10580 (914) 401-7059 (Name, Address and Telephone Number of Person Auth |
|
| October 6, 2022 |
CUSIP No: 60255C885 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. ) * Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 60255C885 (CUSIP Number) Sept |
|
| September 29, 2022 |
MindMed Announces Pricing of Public Offering of Common Shares and Warrants Exhibit 99.2 MindMed Announces Pricing of Public Offering of Common Shares and Warrants New York, September 27, 2022 (GLOBE NEWSWIRE) ? Mind Medicine (MindMed) Inc. (?MindMed?) (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, t |
|
| September 29, 2022 |
Form of 2022 USD Financing Warrant Exhibit 4.1 FORM OF COMMON SHARE WARRANT CUSIP 60255C 182 MIND MEDICINE (MINDMED) INC. Warrant Shares: Date of Issuance: , 2022 (such date, the ?Issue Date?) THIS COMMON SHARE WARRANT (the ?Warrant?) certifies that, for value received, the registered holder hereof or its permitted assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions set f |
|
| September 29, 2022 |
Exhibit 1.1 Mind Medicine (MindMed) Inc. 7,058,823 Common Shares (no par value per share) Warrants to Purchase 7,058,823 Common Shares Underwriting Agreement New York, New York September 27, 2022 RBC Capital Markets, LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed on Schedule I hereto c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street New York, New Yor |
|
| September 29, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264648 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 16, 2022) MindMed (Mind Medicine) Inc. 7,058,823 Common Shares Warrants to Purchase up to 7,058,823 Common Shares We are offering 7,058,823 common shares and accompanying warrants to purchase up to 7,058,823 common shares. Each common share is being sold together with one a |
|
| September 29, 2022 |
MindMed Announces Proposed Public Offering of Common Shares Exhibit 99.1 MindMed Announces Proposed Public Offering of Common Shares New York, September 27, 2022 (GLOBE NEWSWIRE) ? Mind Medicine (MindMed) Inc. (?MindMed?) (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares with accompan |
|
| September 29, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2022 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp |
|
| September 27, 2022 |
Subject to Completion, dated September 27, 2022. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264648 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| September 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of In |
|
| September 14, 2022 |
MindMed Announces Compliance with Nasdaq Listing Requirements Exhibit 99.1 MindMed Announces Compliance with Nasdaq Listing Requirements NEW YORK, Sept. 14, 2022 ? Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the ?Company? or ?MindMed?), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 Mind Medicine (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor |
